Drug-induced inflammation in patients on TNFα inhibitors

Ocular Immunology and Inflammation

Volumn 20, Issue 1, 2012, Pages 2-5

  Cunningham, Emmett T ^a   Pasadhika, Sirichai ^b   Suhler, Eric B ^c,d   Zierhut, Manfred ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Adalimumab; Drug induced uveitis; Etanercept; Granulomatous; Inflixamab; Sarcoidosis

Indexed keywords

ADALIMUMAB; AGENTS ACTING ON THE EYE; ALPHA INTERFERON; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CERTOLIZUMAB PEGOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DIETHYLCARBAMAZINE; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; IBUPROFEN; INFLIXIMAB; METHOTREXATE; METIPRANOLOL; ORAL CONTRACEPTIVE AGENT; PREDNISONE; PROSTAGLANDIN DERIVATIVE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; RIFABUTIN; SULFONAMIDE; TOPIRAMATE; TRIFLUOPERAZINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; USTEKINUMAB; VACCINE;

ACTINOMYCETALES INFECTION; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; BEHCET DISEASE; CANCER RISK; CHORIORETINITIS; CHOROIDITIS; CYTOPENIA; DEMYELINATING DISEASE; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INDUCED INFLAMMATION; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EDITORIAL; ENVIRONMENTAL FACTOR; EYE DISEASE; EYE FLOATER; EYE INFLAMMATION; FATIGUE; GENETIC POLYMORPHISM; GRANULOMA; GRANULOMATOSIS; HEADACHE; HEART FAILURE; HEREDITY; HUMAN; INFLAMMATION; INJECTION SITE REACTION; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; MYCOBACTERIOSIS; MYCOSIS; PERIPHLEBITIS; PHLEBITIS; PNEUMONIA; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SARCOID UVEITIS; SEGMENTAL PERIPHLEBITIS; SIDE EFFECT; SKIN INFLAMMATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TUBERCULOSIS; UVEITIS; VASCULITIS; VISION; VITREOUS OPACITY;

EID: 84856859393     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2011.644383     Document Type: Editorial

References (47)

1. Cunningham ET Jr, Wender JD. Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol. 2010;45(4):352-358.
2. Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica. 2010;224 (Suppl 1):46-53.
3. Lee FF, Foster CS. Pharmacotherapy for uveitis. Expert Opin Pharmacother 2010;11(7):1135-1146.
4. Okada AA. Immunomodulatory therapy for ocular infam-matory disease: a basic manual and review of the literature. Ocul Immunol Infamm. 2005;13(5):335-351. (Pubitemid 41702757)
5. Jabs DA. Treatment of ocular infammation. Ocul Immunol Infamm. 2004;12(3):163-168.
6. Lustig MJ, Cunningham ET Jr. Use of immunosuppres-sive agents in uveitis. Curr Opin Ophthalmol. 2003;14(6): 399-412.
7. Smith JR, Rosenbaum JT. Management of immune mediated uveitis. BioDrugs. 2000;13(1):9-20.
8. Solomon SD, Cunningham ET Jr. Use of corticosteroids and non-corticosteroid immunosuppressive agents in patients with uveitis. Comp Ophthal Update. 2000;1(5):273-286.
9. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular infammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492-513.
10. Pato E, Muñoz-Fernández S, Francisco F, et al. Uveitis Working Group from Spanish Society of Rheumatology. Systematic review on the effectiveness of immunosuppres-sants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. 2011;40(4):314-323.
11. Rosenbaum JT. Future of biological therapy for uveitis. Curr Opin Ophthalmol. 2010;21(6):473-477.
12. Hemmati HD, Dunn JP. Biologic therapy for uveitis. Expert Rev Ophthalmol. 2010;5(2):225-239.
13. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18(6):481-486. (Pubitemid 351339402)
14. Lim L, Suhler EB, Smith JR. Biologic therapies for infamma-tory eye disease. Clin Exp Ophthalmol. 2006;34:365-374 (Pubitemid 44137557)
15. Sharma SM, Nestel AR, Lee RWJ, Dick AD. Clinical review: anti-TNF-α therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Infamm. 2009;17(6):403-414.
16. Deuter CME, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M. Behçet's disease: ocular effects and treatment. Prog Ret Eye Res. 2008;27:111-136.
17. Lee RWJ, Dick AD. Treat early and embrace the evidence in favour of anti-TNF-α therapy for Behçet's uveitis. Br J Ophthalmol. 2010;94(3):269-270.
18. Qian Y, Acharya NR. Juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2010;21(6):468-472.
19. Cordero-Coma M, Salom D, Díaz-Llopis M, López-Prats MJ, Calleja S. Golimumab for uveitis. Ophthalmology. 2011; 118(9):1892.e3-4.
20. Tlucek PS, Stone DU. Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea. 2011; Sep 20. [Epub ahead of print]
21. Sfkakis PP. The frst decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180-210.
22. Goldstein DA. Uncovering the risk of immunosuppressive therapy in patients with uveitis. Arch Ophthalmol. 2009; 127(6):799-800.
23. Cunningham ET Jr, Zierhut M. TNF inhibitors for uveitis: balancing effcacy and safety. Ocul Immunol Infamm. 2010; 18(6):421-423.
24. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10):3248-3252. (Pubitemid 47585419)
25. Fonollosa A, Artaraz J, Les I, et al. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Infamm. 2012;20(1):44-48.
26. Seve P, Varron L, Broussolle C, Denis P, Kodjikian L. Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Infamm. 2012;20(1):59-60.
27. Daïen CI, Monnier A, Claudepierre P, et al; Club Rhumatismes et Infammation (CRI). Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883-886.
28. Toussirot E, Pertuiset E. TNFalpha blocking agents and sar-coidosis: an update. Rev Med Interne. 2010;31:828-837.
29. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor α therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum. 2010;39:313-319.
30. Roux CH, Brocq O, Leccia N, et al. New-onset psoriatic pal-moplantaris pustulosis following infiximab therapy: a class effect? J Rheumatol. 2007;34:434-437.
31. Palucka AK, Blanck JP, Bennett I, Pascual V, Banchereau J. Cross regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA. 2005;102:3372-3377. (Pubitemid 40328052)
32. Ladoyanni E, Nambi R. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol. 2005;4:221-222.
33. Lee YB, Lee JI, Park HJ, Cho BK, Oh ST. Interferon-alpha induced sarcoidosis with cutaneous involvement along the lines of venous drainage. Ann Dermatol. 2011;23(2):239-241.
34. Doycheva D, Deuter C, Stuebiger N, Zierhut M. Interferon-alpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):675-680. [Epub 2008 Nov 26]
35. Viguier M, Richette P, Bachelez H, Wendling D, Aubin F. Paradoxical adverse effects of anti-TNF-a treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009;5(4):421-431.
36. Levine D, Switlyk SA, Gottlieb A, Cutaneous lupus erythe-matosus and anti-TNF-α therapy: a case report and review of the literature. J Drugs Derm. 2010;9(10):1283-1287.
37. Cullen G, Kroshinsky D, Cheifetz AS, Korenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in infammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011 Sep 29. [Epub ahead of print]
38. Akahoshi M, Ishihara M, Remus N, et al. Association between IFNA genotype and the risk of sarcoidosis. Hum Genet. 2004; 114:503-509. (Pubitemid 38678930)
39. Zampino MR, Corazza M, Borghi A, Marzola A, Virgili A. HLA typing in an IFN-alpha-induced scar sarcoidosis: possible pathogenetic and clinical implications. Acta Derm Venereol. 2009;89:661-662.
40. Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. Surv Ophthalmol. 1998;42(6):557-570. (Pubitemid 28272743)
41. Moorthy RS, Valluri S. Ocular toxicity associated with systemic drug therapy. Curr Opin Ophthalmol. 1999;10(6): 438-446.
42. Fraunfelder FW. Drug-induced ocular infammatory diseases. Drugs Today (Barc). 2007; 43(2):117-123.
43. Jabbarpoor Bonyadi MH, Soheilian R, Soheilian M. Topiramate-induced bilateral anterior uveitis associated with hypopyon formation. Ocul Immunol Infamm. 2011; 19(1):86-88.
44. Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. Cutan Ocul Toxicol. 2010; 29(1): 26-29.
45. Wefers Bettink-Remeijer M, Brouwers K, van Langenhove L, et al. Uveitis-like syndrome and iris transillumina-tion after the use of oral moxifoxacin. Eye (Lond). 2009; 23(12):2260-2262.
46. Willermain F, Deforenne C, Bouffoux C, Janssens X, Koch P, Caspers L. Uveitis-like syndrome and iris transillumi-nation after the use of oral moxifoxacin. Eye (Lond). 2010; 24(8):1419.
47. Hinkle DM, Dacey MS, Mandelcorn E, et al. Bilateral uveitis associated with fuoroquinolone therapy. Cutan Ocul Toxicol. 2011 Oct 8. [Epub ahead of print]